×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NYSE:LLY

Eli Lilly and Price Target, Predictions & Analyst Ratings

$325.62
+12.90 (+4.13%)
(As of 06/24/2022 07:00 PM ET)
Add
Compare
Today's Range
$319.01
$325.82
50-Day Range
$278.73
$325.62
52-Week Range
$220.20
$325.82
Volume
5.45 million shs
Average Volume
3.03 million shs
Market Capitalization
$309.39 billion
P/E Ratio
48.24
Dividend Yield
1.20%
Price Target
$311.65

Eli Lilly and (NYSE:LLY) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 17 Analyst Ratings

Consensus Analyst Price Target

$311.65
-4.29% Downside
High Price Target$369.00
Average Price Target$311.65
Low Price Target$264.00
TypeCurrent
6/27/21 to 6/27/22
1 Month Ago
5/28/21 to 5/28/22
3 Months Ago
3/29/21 to 3/29/22
1 Year Ago
6/27/20 to 6/27/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
14 Buy rating(s)
15 Buy rating(s)
14 Buy rating(s)
9 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$311.65$307.94$293.06$221.42
Predicted Upside-4.29% Downside15.22% Upside13.58% Upside14.47% Upside
Get Eli Lilly and Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.


LLY Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LLY Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eli Lilly and Stock vs. The Competition

TypeEli Lilly andMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.71
2.52
Consensus RatingModerate BuyBuyBuy
Predicted Upside-4.29% Downside439.12% Upside29.94% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1092
71.56%
Underperform Votes
434
28.44%
Avg. Outperform Votes
170
66.93%
Avg. Underperform Votes
84
33.07%
Avg. Outperform Votes
839
69.11%
Avg. Underperform Votes
375
30.89%

Historical Eli Lilly and Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/1/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$340.00 ➝ $355.00+13.26%
5/23/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$341.00+14.10%
5/2/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vamil Divan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$315.00 ➝ $356.00+21.86%
4/29/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$364.00 ➝ $369.00+24.13%
4/29/2022Wells Fargo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$280.00 ➝ $305.00+2.60%
4/12/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$234.00 ➝ $264.00-14.55%
3/17/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$300.00 ➝ $315.00+13.95%
3/10/2022Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$286.00+8.83%
1/21/2022DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Elmar Kraus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$291.00+19.69%
1/3/2022Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$250.00 ➝ $300.00+11.40%
12/20/2021Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$270.00 ➝ $305.00+14.05%
12/20/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$280.00 ➝ $325.00+21.53%
12/16/2021BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$311.00 ➝ $320.00+16.30%
11/24/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$262.00 ➝ $301.00+14.90%
9/29/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$210.00 ➝ $265.00+19.58%
8/30/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$250.00 ➝ $300.00+15.50%
8/9/2021Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$225.00 ➝ $300.00+13.88%
6/24/2021Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Overweight$245.00 ➝ $300.00+26.03%
12/10/2020Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$147.00 ➝ $183.00+15.82%
6/16/2020Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$182.00+28.60%
4/24/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$146.00 ➝ $167.00+2.83%
4/20/2020UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$157.00 ➝ $158.00+0.13%
(Data available from 6/27/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Eli Lilly and Price Target - Frequently Asked Questions

What is Eli Lilly and's consensus rating and price target?

According to the issued ratings of 17 analysts in the last year, the consensus rating for Eli Lilly and stock is Moderate Buy based on the current 3 hold ratings and 14 buy ratings for LLY. The average twelve-month price prediction for Eli Lilly and is $311.65 with a high price target of $369.00 and a low price target of $264.00. Learn more on LLY's analyst rating history.

Do Wall Street analysts like Eli Lilly and more than its competitors?

Analysts like Eli Lilly and stock more than the stock of other Medical companies. The consensus rating for Eli Lilly and is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how LLY compares to other companies.

Do MarketBeat users like Eli Lilly and more than its competitors?

MarketBeat users like Eli Lilly and stock more than the stock of other Medical companies. 71.56% of MarketBeat users gave Eli Lilly and an outperform vote while medical companies recieve an average of 67.07% outperform votes by MarketBeat users.

Does Eli Lilly and's stock price have much upside?

According to analysts, Eli Lilly and's stock has a predicted upside of 14.78% based on their 12-month price targets.

What analysts cover Eli Lilly and?

Eli Lilly and has been rated by JPMorgan Chase & Co., Mizuho, Morgan Stanley, SVB Leerink, The Goldman Sachs Group, and Wells Fargo in the past 90 days.

This page (NYSE:LLY) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.